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Summary We report a family with the Li-Fraumeni syndrome (LFS) in whom we have been unable to detect
a mutation in the coding sequence of the p53 gene. Analysis of linkage to three polymorphic markers within
p53 enabled direct involvement of p53 to be excluded. This is the first example of a LFS family in whom
exclusion of p53 has been possible. Four affected members of the family with sarcoma or premenopausal
breast cancer showed increased expression of p53 protein in their normal tissues as detected by immunohis-
tochemistry. It therefore appears that the LFS phenotype has been conferred by an aberrant gene, showing a
dominant pattern of inheritance, which may be acting to compromise normal p53 function rather than by a
mutation in p53 itself. In order to try to determine the chromosomal location of this putative gene, we have
carried out studies of linkage to candidate loci. By these means we have excluded involvement of RbN and
BRCAJ on chromosomes 13q and 17q respectively. The MDM2 oncogene on chromosome 12q was considered
to be the prime candidate as MDM2 is amplified in sarcomas and the MDM2 product binds to p53.
Furthermore, p53 mutation and amplification of MDM2 have been shown to be mutually exclusive events in
tumour development. Linkage analysis to two polymorphic markers within MDM2 yielded a three-point LOD
score of - 5.4 at a recombination fraction equal to zero. Therefore MDM2 could be excluded. It is possible
that the gene which is responsible for cancer susceptibility in this family, possibly via interaction with p53, will
be important in the histogenesis of breast cancer in general. We are now carrying out further studies to locate
and identify this gene.
Germline mutations in the p53 tumour-suppressor gene were
initially reported in five families with the Li-Fraumeni syn-
drome (LFS) (Malkin et al., 1990). The principal components
of LFS include bone and soft-tissue sarcoma in children and
young adults and premenopausal breast cancer. Brain
tumours, acute leukaemia and adrenocortical carcinoma also
occur to excess in these families (Birch et al., 1990; Garber et
al., 1991). Subsequent reports of other LFS families with
germline p53 mutations supported the initial conclusion that
such mutations formed the genetic basis ofcancer predisposi-
tion in families with this syndrome (Srivastava et al., 1990;
Law et al., 1991; Toguchida et al., 1992). However, more
recent data suggest that coding mutations in the p53 gene
occur in only approximately 50% of families with LFS
(Brugieres et al., 1993; Birch et al., 1994).
Barnes et al. (1992) have reported a family with features
suggestive of LFS, in whom no constitutional mutation in
the p53 gene could be detected, but in whom abnormally
high levels of wild-type p53 protein in normal cells of
affected family members were found. The authors suggested
that in this family a germline mutation outside the p53
coding region was affecting expression of p53 protein, and
that this resulted in an enhanced cancer risk.
We have previously reported a family with LFS in whom
there was a lack of shared alleles for a polymorphism in p53
in a pair of affected sibs (Santibaniez-Koref et al., 1991). We
have now obtained a more detailed pedigree, extended the
data on linkage to p53 and have investigated the expression
of p53 protein in members of this family. We have also
examined the possibility of linkage to candidate loci other
than p53.
Materials and methods
The family was ascertained through a female proband who
was diagnosed with a myxoid liposarcoma at the age of 30
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and who subsequently developed invasive carcinoma of the
breast at the age of 35. Family history revealed rhabdo-
myosarcoma in the proband's mother, diagnosed at the age
of 52; carcinoma of the rectum in her maternal aunt, causing
death at the age of45; and carcinoma of the breast at age 29
in the proband's maternal first cousin. All these cancers were
histologically reviewed or confirmed by reference to medical
records. On the basis of this cluster of cancers the family was
classified as having LFS (Garber et al., 1991).
Interviews with several other members of the family estab-
lished that there was a strong history of cancers in other
branches of the family, notably premenopausal breast cancer
and prostate cancer. An extended pedigree covering five
generations with 137 documented individuals, 29 of whom
were medically confirmed as having malignant disease, was
constructed. Biological samples were available from ten
cancer-affected family members and 11 unaffected family
members. An abbreviated pedigree of the family is shown in
Figure 1.
DNA was extracted from blood or fixed tissue from
affected and unaffected members of the family indicated in
Figure 1. The entire coding sequence of the p53 gene had
been analysed in the sample from the proband, using stan-
dard procedures and oligonucleotide primers as previously
reported (Birch et al., 1994).
Formalin-fixed tumour and normal tissue was available
from persons 97, 99, 163, 174 and tumour only from 221
(Figure 1). Expression of p53 protein in tissue sections from
these individuals was assessed by immunohistochemical
analysis using the rabbit polyclonal p53 antibody CM1
(Bafrtek et al., 1991; Midgley et al., 1992). Staining with CMI
was repeated three times for each section and independently
assessed by two of us (A.M.K. and J.M.B.). In addition,
sections from person 97 were also reviewed by D.P.L.
Individuals from whom constitutional samples of DNA
were available were typed for assessment of linkage to a
number of candidate loci, including 17p, 17q, RbH and 12q.
The PCR markers used in this study are listed in Table I and
include the seven markers flanking the BRCAJ gene on
chromosome 17q used in the recent analysis of linkage in
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Figure 1 Abbreviated pedigree of family with LFS. 0, Male without cancer; 0, female without cancer; *, male with cancer; 0,
female with cancer; /, deceased person. PRO, carcinoma prostate; ABD, abdominal cancer; B, carcinoma breast; BB, bilateral
carcinoma breast; PAN, carcinoma pancreas; REC, carcinoma rectum; RMS, rhabdomyosarcoma; OV TER, bilateral benign
ovarian teratoma; LIPO, liposarcoma. Numbers to right of cancer type indicate age at diagnosis; numbers above and to right of
person symbol are person identification numbers; *indicates persons typed for linkage, + indicates persons who stained positively
with CMI antibody; - indicates person who was negative for staining with CM1 antibody; A indicates person appears twice on
pedigree.
Table I PCR-formatted markers used in this study
Locus Marker Reference
D17S250 mfdl5 Easton et al. (1993)
D17S579 mfdl88 Easton et al. (1993)
D17S587 46E6 Easton et al. (1993)
D17S588 42D6 Easton et at. (1993)
GH GH Easton et al. (1993)
NMEJ NM23 Easton et al. (1993)
THRAM THRAI Easton et al. (1993)
TP53 p53 BstUI polymorphism Harris et al. (1986)
TP53 p53 CA repeat Jones & Nakamura (1992)
TP53 p53 TAAAA repeat Futreal et al. (1991)
RB1 RB) XbaI polymorphism McGee et al. (1990)
MDM2 MDM2 NlaIV leader Heighway et al. (1994)
polymorphism
MDM2 MDM2 NlaIV intron Heighway et al. (1994)
polymorphism
familial breast and ovarian cancer (Easton et al., 1993), three
markers within the p53 gene (Harris et al., 1986; Futreal et
al., 1991; Jones et al., 1992), a polymorphic marker within
the RB1 gene (McGee et al., 1990) and two markers within
The MDM2 gene on chromosome 12q (Heighway et al.,
1994). Primers used to amplify polymorphisms within the
MDM2 gene are as follows. The positions are detailed in
Figure 2 and the sequences is written 5' to 3'.
5' leader
NlalV
(al a2)
a GCGCGAGCTTGGCTGCTTCT
b TCCCTCAAGACTCCCCAGTTT
c G-CTTTGCGGAGGT&TTTGTTGGA
d ATCTGTGAGGTGGTTACAGCAC
Conditions for primer set a/b are as detailed by Heighway
et al. (1994). Amplification of the fragment containing the
second polymorphic NlaIV site (a3a4) are as follows. Reac-
tions were carried out in a 100 1sl volume using 0.5 1tg ofeach
primer (c,d), 2.5 units of Dynazyme polymerase (Flow), reac-
tion buffer (Flow) and dNTPs (0.25 mM). A 100 ng aliquot of
chromosomal DNA was used as starting material. An initial
denaturation step at 96°C for 2min was followed by 30
cycles of 57°C for 1 min, 74C for 2 min and 96°C for 1 min.
A final cycle of 57°C for 1 min and 74°C for 4 min completed
the PCR reaction. PCR products were restricted with NlaIV
(NEB) and visualised on 2-2.5% agarose gels (Seakem
GTG).
Typing of other microsatellite markers was carried out as
previously described (Teare et al., 1993). Southern analysis of
RSaI-digested genomic DNA as described by Heighway et al.
(1986) was used to type a marker at D17S34 on chromosome
17p (Kondoleon et al., 1987).
In the linkage calculations we have assumed a dominant
model with gene frequency 0.0001 as found by Lustbader et
al. (1992).
NlaIV
(a3 a4)
I 1- xxxxxxxxx ATG
NPCR-resistant sequence
\ \1-
a b
40-
c d
Primers
Splice
....TGAGGAGCAGgtactgg ----------------- intron ------------------tttccttgtagGCAAATGTG....
Figure 2 The 5' region of the MDM2 gene and the polymorphic NlaIV sites, PCR primers and position of the 700 bp intron.
Primers a, b and c lie within the published sequence. The intron encodes a region resistant to PCR, amplifications across which are
difficult. The sequence flanking the splice sites is detailed. Lower-case base sequence denotes intron.1178 J.M. BIRCH et al.
Penetrance parameters were estimated from the family
itself, as follows: a person with any cancer was considered to
be affected. Penetrance parameters for non-gene carriers were
calculated from the North-West Regional Cancer Registry
figures for age-specific incidence of cancer. Following the
argument of Easton et al. (1993), separate liability classes
were assigned for affected and unaffected pedigree members.
Two additional liability classes were assigned to take into
account the additional cancer phenotype information on
immunostaining. The positive-staining phenotype is treated
as 100% penetrant regardless of age. Thus, a person showing
positive staining with CM1 antibody is considered to be a
gene carrier and a person negative for staining a non-gene
carrier. Penetrance estimates are shown in Table II.
As a partial check on the above model, the family was
analysed considering only those individuals with breast
cancer or sarcoma to be affected, and applying the familial
breast cancer model specified by Easton et al. (1993). Those
affected with sarcoma were assigned to the affected under age
30 class. Under this model the results of staining were
disregarded.
LOD scores were calculated using the LINKAGE prog-
ramme. A LOD score of 3 is considered to be significant
evidence of linkage. Negative LOD scores (less than -2)
enable linkage to be excluded.
Table II Table of penetrance estimates for Li-fraumeni model
Probability of affection by genotype
Age group (A = disease allele)
(years) AA Aa aa
Unaffected
<30 0.0800 0.0800 0.0053
30-39 0.2400 0.2400 0.0136
40-49 0.3200 0.3200 0.0361
50-59 0.4500 0.4500 0.0925
60-69 0.5400 0.5400 0.1942
70-79 0.8500 0.8500 0.3326
> 80 0.9000 0.9000 0.4740
Affected
<30 0.0027 0.0027 0.0002
30-39 0.0094 0.0094 0.0008
40-49 0.0094 0.0094 0.0023
50-59 0.0110 0.0110 0.0060
60-69 0.0110 0.0110 0.0119
70-79 0.0310 0.0310 0.0189
)80 0.0310 0.0310 0.0238
Positive immunostaining I 1 0
Negative immunostaining 0 0 1
Results
Linkage analyses
As previously reported, no mutations were detected in the
coding sequence of the p53 gene in the proband from this
family (Birch et al., 1994). Therefore, we carried out linkage
studies to candidate loci. In order to address the possibility
of intronic or control sequence mutations in p53 the family
was typed for three markers within the p53 gene and a
further marker on chromosome 17p. RbH has been shown to
be involved in human sarcomas, the principal component of
LFS, and was therefore considered to be a candidate (Strat-
ton et al., 1989). Breast cancers are common in families with
LFS and occurred in a number of members of the present
family. We therefore also analysed the family for linkage to
the breast cancer gene BRCAI. Table III shows LOD scores
for these markers. There are negative LOD scores for each of
the p53 markers. The main reason for this is that the sisters
with person numbers 097 and 099 do not share any alleles for
two of the markers [p53 (BstUI), p53(TAAAA)] and do not
share maternal alleles for the third [p53(CA)]. Negative LOD
scores for each of the remaining markers were also obtained,
effectively excluding BRCAJ and RbJ as candidate loci in
this family.
Under the familial breast cancer model, the criteria for
affection, i.e. breast cancer or sarcoma, meant that fewer
individuals were considered to be affected under this model
than under the Li-Fraumeni model. The results, however, are
consistent with those presented above with negative LOD
scores for each of the p53 markers. Involvement of p53 can
therefore be excluded under this model also.
Staining withp53 antibody
Results of immunostaining in sections of the breast car-
cinoma which occurred in person number 99 showed intense
nuclear staining with CM1 antibody with a high frequency in
the tumour cells. In sections of normal breast tissue also,
intense nuclear staining was seen in fibroblasts and ductal
epithelium with a high frequency, that is virtually all cells
were stained. This is illustrated in Figure 3, which shows a
section in which nuclear staining in both stromal and tumour
tissue is marked. Sections of normal and tumour material
were also available from the proband, who had a myxoid liposarcoma (person number 163), and from persons 97 and
174, both of whom also had carcinoma of the breast. These
three individuals showed the same pattern of staining as
person 99, with marked nuclear staining with CM1 antibody in a high proportion of cells in both tumour tissue and
normal tissue. The results of staining and assessment of
results were consistent between reviewers and between stain-
ing batches.
Table III LOD scores calculated under Li-faumeni model
THETA Marker locus 0.000 0.001 0.01 0.1 0.2 0.3
RbN gene -3.007 -2.368 -1.464 -0.462 -0.191 -0.018 D17S34 -1.818 -1.507 -0.778 -0.025 0.049 0.027 p53 (BstUI) - 3.651 - 2.495 - 1.519 - 0.508 - 0.224 - 0.088 p53 (CA) - 1.729 - 1.729 - 1.667 - 0.621 - 0.230 - 0.075 p53 (TAAAA) - 3.377 - 2.230 - 1.271 - 0.386 - 0.185 - 0.084 D17S250 -1.135 -0.946 -0.360 -0.195 0.130 0.041 D17S579 -1.640 -1.307 -0.570 -0.119 0.136 0.071 D17S587 - 1.151 - 1.047 - 0.604 - 0.023 - 0.012 - 0.028 D17S588 -1.135 -0.946 -0.360 0.195 0.130 0.041
GH -1.784 -1.541 -0.874 -0.123 -0.013 0.003 NMEJ -1.502 -1.402 -0.958 -0.21 -0.061 -0.018
THRA1 - 1.598 - 1.451 - 0.913 - 0.209 - 0.104 - 0.059
Gene frequency 0.0001. Lifetime penetrance: gene carriers, 90%; non-gene carriers, 45%. Affected = all cancers. p53-positive stain has probability of one of being gene carrier.LINKAGE STUDIES IN A LI-FRAUMENI SYNDROME 1179
Sections of a pancreatic carcinoma occurring in a relative
by marriage, and therefore not in the same lineage as the
proband (person 221) were also available. This material
showed no staining with CM1 antibody, providing a negative
control. Sections of a sporadic colon carcinoma which was
known to stain positively with CM1 were processed at the
same time to provide a positive control. Figure 4 shows a
section containing both tumour tissue and normal tissue. The
tumour tissue shows strongly positive nuclear staining in all
cells, but no staining is seen in the normal tissue. This
staining pattern is typical of sporadic tumours with somatic
p53 mutations.
These results suggested that either a gene segregating with
the cancers in this family was interacting with p53 to stabilise
the p53 product or that p53 expression was elevated to
compensate for a defect in another gene. The MDM2 onco-
gene on chromosome 12q was considered to be the prime
candidate as the MDM2 product binds to p53 protein and
MDM2 is amplified in a subset of soft-tissue sarcomas
(Momand et al., 1992; Oliner et al., 1992). Furthermore, a
recent study by Leach et al. (1993) has suggested that ampli-
fication of MDM2 and mutation of p53 may be mutually
exclusive events in this type of malignancy. This idea has
been supported in the analysis of MDM2 amplification/p53
mutation in human gliomas (Reifenberger et al., 1993).
Analysis ofMDM2
Following typing of the family for the biallelic intragenic
polymorphisms in MDM2 (Figure 5) three-point LOD scores
were calculated. At 6 = 0 the LOD score was - 5.440, largely
because persons 174 and 163 do not share haplotypes by
descent with sisters 97 and 99. At 0 = 0.1, 0.2 and 0.3 the
LOD scores were 1.294, 1.416 and 0.996 respectively. The
Figure 3 Section of carcinoma ofbreast from person 99 showing
intense nuclear staining with CM1 antibody in virtually every cell
in both the stromal and tumour tissue.
Figure 4 Section from sporadic colon carcinoma showing strong
nuclear staining in tumour cells but no staining in adjacent
normal tissue.
a4
~~a3
E - " r o cr C OD
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Figure 5 Key family members typed with the MDM2 polymor-
phisms. Affected individuals staining positive for p53 in normal
tissue do not share alleles by descent. Marker track (M) is a
OIX174/HaeIII digest. Individual numbers refer to those on the
pedigree.
maximum LOD score 1.47 was found at 0 = 0.16. These
results excluded MDM2 as a candidate but suggested the
possible presence of a gene on chromosome 12q at a distance
from MDM2. Therefore the family was typed for additional
markers on chromosome 12q flanking the MDM2 gene. Re-
sults for these markers, however, did not support linkage to a
gene adjacent to MDM2.
Discussion
Wild-type p53 protein has a short half-life of a few minutes
and is not detectable immunohistochemically. Mutant pro-
teins in general have a much longer half-life, typically several
hours. This results in accumulation of the protein which can
then be detected by immunohistochemistry (Lane & Ben-
chimol, 1990). Nuclear staining with p53 antibody is fre-
quently seen in tumour tissue, and often there is a correlation
between staining and the presence of a p53 mutation,
although false positives and false negatives have also been
seen (Bartek et al., 1991; Andersen et al., 1993).
In the present family no mutation was found in the coding
sequence of p53, and negative LOD scores were obtained in
an analysis of linkage to three polymorphic markers within
p53. The direct involvement of the p53 gene in the segrega-
tion of cancer susceptibility in this family can therefore be
rejected. This is the first example of a LFS family in whom
direct involvement of p53 has been excluded by linkage.
Other candidate loci have therefore been examined by link-
age analysis. Results of the initial linkage analyses effectively
excluded RbH and BRCA1. This result, together with the
results for p53 and D17S34, cover a large part of
chromosome 17.
Positive staining with p53 antibody, however, which
affected nearly every cell, was seen in normal tissue as well as
tumour tissue in four affected family members. CMI anti-
body is highly specific, and the presence of positively stained
cells in normal tissue is extremely rare (Barnes et al., 1992;
Midgley et al., 1992). We have observed positive staining in
normal tissues in individuals with certain germline mutations
in the p53 gene. In these patients, however, when compared
with the present family there was a much more hetero-
geneous pattern of staining, with variation in the frequency1180 J.M. BIRCH et al.
and intensity (A.M. Kelsey et al., in preparation). The result
in the present family implies the presence of abnormally high
constitutional levels of p53 protein in these cancer-affected
individuals. Studies are planned to try to quantify the levels
of p53 in affected individuals by enzyme-linked immunosor-
bent assay (ELISA). The immunostaining result is similar to
that observed by Barnes et al. (1992) in a family with a
Li-Fraumeni-like pattern of cancers. In their family, consti-
tutional expression of abnormally large quantities of p53
protein was confirmed by immunoprecipitation and immuno-
blotting and quantitative ELISAs. However, because their
family was much smaller than the present family, with many
fewer cancer-affected members, Barnes et al. (1992) were
unable to conduct linkage analyses to exclude p53.
In the absence of a p53 mutation in the present family the
increased expression must be assumed to be wild-type p53
protein. Therefore, another constitutional lesion which
interacts with p53 and which confers a familial cancer
phenotype consistent with LFS must be present in these
individuals. This lesion may be acting to stabilise normal p53
protein, resulting in high levels detectable by immunohisto-
chemistry. Alternatively, it may be that increased levels of
p53 protein are being produced to compensate for a defect
which is pushing the cell to proliferate, thereby acting as a
brake on proliferation. The pattern of cancers and the
presence of this unusual immunostaining phenotype in four
affected family members clearly indicate that this trait is
dominant. Furthermore, we have recently obtained skin biop-
sies from a number of family members and their spouses.
The biopsies from two affected family members showed posi-
tive staining with CM1 anibody, but all the spouse control
biopsies were negative.
Because the MDM2 oncogene product binds to the p53
protein and can overcome the suppression of transformed
cell growth exerted by wild-type p53, we considered MDM2
to be a good candidate in this family, but linkage analysis to
two intragenic MDM2 markers yielded a highly negative
LOD score at zero recombination, thereby excluding MDM2.
Although positive LOD scores were obtained at a recombina-
tion distance from MDM2, analysis of further markers on
chromosome 12q did not support linkage to this region.
Therefore this small positive LOD score can be assumed to
be spurious.
There are many similarities between our family and the
family described by Barnes et al. (1992) in terms of the p53
staining phenotype, and in the cancers seen. In both families
the proband had a double primary carcinoma of the breast
and soft-tissue sarcoma, both diagnosed under the age of40,
and included a family member with early-onset colorectal
carcinoma. The same gene may be responsible for the cancer
predisposition seen in both families. The apparent constitu-
tional increase in the level of wild-type p53 protein may
indicate that the normal function of p53 is being compro-
mised by a gene other than MDM2 and by this indirect
mechanism confers a similar cancer phenotype to that confer-
red by mutations in p53 itself. By implication, all cells in
individuals carrying this trait would manifest a constitutive
p53 dysfunction. It is of interest that in LFS families with
germline p53 mutations over half the cancers were diagnosed
before 30 years of age (Birch et al., 1994), but in the present
family and the family described by Barnes et al. (1992) most
cancers were diagnosed over the age of 30.
The majority of germline p53 mutations found in LFS
families are missense mutations, resulting in an altered pro-
tein product, many of which appear to show a gain of
function (Dittmer et al., 1993; Birch et al., 1994). It may be,
therefore, that, although the type of cancers seen in families
in which another gene effectively negates normal p53 are
similar to those found in families with germline mutations in
the p53 gene, a less highly penetrant cancer phenotype results
in these families in terms of age of onset of cancers, com-
pared with those families with germline gain-of-function
mutations in the p53 gene itself. In carriers of germline p53
mutations loss of the wild-type p53 allele would be required
for full loss of normal p53 function. If it is assumed that the
inherited trait in the present family results in constitutional
loss of p53 function, then the higher penetrance in the
families with germline missense mutations may provide addi-
tional support for the notion of gain of function in such
mutations. Alternatively, the relatively mild phenotype in the
present family associated with high constitutional levels of
wild-type p53 may indicate that in this family the p53 pro-
duced retains at least partial function.
Although Li-Fraumeni families are rare, breast cancer is
one of the principal component cancers in families with this
syndrome. It is possible therefore that the gene responsible
for cancer predisposition in this family will be important in
the histogenesis of breast cancer in general, and may be
involved in at least a proportion of familial breast cancer not
accounted for by the BRCAJ gene. We are therefore continu-
ing our studies to locate the responsible gene in this highly
informative family.
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